Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.
Industry, Sector and Symbol
Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:MSL
CUSIPN/A
Phone+1-905-7260995
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5.18%
Return on Equity-2.51%
Return on Assets-1.32%
Miscellaneous
EmployeesN/A
Outstanding Shares117,355,000
Market CapC$0.00
Merus Labs International (TSE:MSL) Frequently Asked Questions
What is Merus Labs International's stock symbol?
Merus Labs International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MSL."
Who are Merus Labs International's key executives?
Merus Labs International's management team includes the folowing people:
- Michael S. Cloutier, Independent Chairman of the Board
- Barry Fishman, Chief Executive Officer, Director
- Michael Scott Bumby, Chief Financial Officer
- Robert McLay, Vice President - Sales and Marketing
- Frank Rotmann, Vice President and Head of European Operations
- Robert Bloch M.D., Director
- Theresa Sheila Firestone, Independent Director
- David D. Guebert CPA, Independent Director
- Robert S. Pollock, Independent Director
- Timothy G. Sorensen, Independent Director
Has Merus Labs International been receiving favorable news coverage?
Media coverage about MSL stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merus Labs International earned a news impact score of 0.18 on Accern's scale. They also gave media headlines about the specialty pharmaceutical company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Merus Labs International.
How do I buy shares of Merus Labs International?
Shares of MSL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Merus Labs International's stock price today?
One share of MSL stock can currently be purchased for approximately C$1.65.
How can I contact Merus Labs International?
Merus Labs International's mailing address is 100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151, TORONTO, ON M5K 1H1, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-7260995.
MarketBeat Community Rating for Merus Labs International (TSE MSL)
MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe MSL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MSL will underperform the S&P 500 over the long term. You may vote once every thirty days.
